Laurent P. Rivory

Laurent P. Rivory

Auto-generated profile, based on publicly available information

Laurent P. Rivory

University of Sydney

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
SCStephen J. Clarke
Stephen J. Clarke
LRLaurent P. Rivory
Laurent P. Rivory

1 April 2003 in The Lancet Oncology
Verified
Journal Article
Closed access
KSKellie A Slaviero
Kellie A Slaviero
SCStephen J Clarke
Stephen J Clarke
LRLaurent P Rivory
Laurent P Rivory

23 July 2002 in British Journal of Cancer
Verified
Journal Article
Open access
LRL P Rivory
L P Rivory
KSK A Slaviero
K A Slaviero
SCS J Clarke
S J Clarke
Inflammatory disease states (infection, arthritis) are associated with reduced drug oxidation by the cytochrome P450 3A system. Many chemotherapy agents are metabolised through this pathway, and disease may therefore influence inter-individual differences in drug pharmacokinetics. The purpose of this study was to assess cytochrome P450 3A function in patients with advanced cancer, and its relation to the acute-phase response. We evaluated hepatic cytochrome P450 3A function in 40 patients with advanced cancer using the erythromycin breath test. Both the traditional C20min measure and the recently proposed 1/TMAX values were estimated. The marker of acute-phase response, C-reactive protein and the pro-inflammatory cytokines IL-6, IL-1β, TNFα and IL-8 were measured in serum or plasma at baseline. Cancer patients with an acute phase response (C-reactive protein >10 mg l−1, n=26) had reduced metabolism as measured with the erythromycin breath test 1/TMAX (Kruskal–Wallis Anova, P=0.0062) as compared to controls (C-reactive protein 10 mg l−1, n=14). Indeed, metabolism was significantly associated with C-reactive protein over the whole concentration range of this acute-phase marker (r=−0.64, Spearman Rank Correlation, P<0.00001). C-reactive protein serum levels were significantly correlated with those of IL-6 (Spearman coefficient=0.58, P<0.0003). The reduction in cytochrome P450 3A function with acute-phase reaction was independent of the tumour type and C-reactive protein elevation was associated with poor performance status. This indicates that the sub-group of cancer patients with significant acute-phase response have compromised drug metabolism, which may have implications for the safety of chemotherapy in this population.

1 October 1996 in Biochemical Pharmacology
Verified
Journal Article
Closed access
LRLaurent P. Rivory
Laurent P. Rivory
MBMark R. Bowles
Mark R. Bowles
Jacques RobertJacques Robert
Jacques Robert
SPSusan M. Pond
Susan M. Pond

1 January 2005 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
DCDavid G Le Couteur
David G Le Couteur
RFRobin Fraser
Robin Fraser
SHSarah Hilmer
Sarah Hilmer
LRLaurent P Rivory
Laurent P Rivory
AMAllan J McLean
Allan J McLean

9 May 2007 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
HGHoward Gurney
Howard Gurney
MWM Wong
M Wong
RBR L Balleine
R L Balleine
LRL P Rivory
L P Rivory
AMA J McLachlan
A J McLachlan
HSH Schran
H Schran